Expression and prognostic value of SULT1A2 in bladder cancer.
SULT1A2
biomarker
bladder cancer
oncogene
prognosis
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
20
09
2020
accepted:
02
03
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
ppublish
Résumé
Sulfotransferase Family 1A Member 2 (SULT1A2) is a protein coding gene. Several studies have reported that SULT1A2 may have a chemical carcinogenic effect if expressed as a functional protein. The present study aimed to investigate the expression and potential role of SULT1A2 in bladder cancer (BC). Data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases were used to analyze SULT1A2 expression in BC. In addition, reverse transcription-quantitative PCR and western blot analyses were performed to detect SULT1A2 expression in BC cells and tissues. Immunohistochemistry analysis was performed on 100 formalin-fixed, paraffin-embedded BC tissues and corresponding adjacent normal bladder tissues (ANBTs) to verify SULT1A2 expression and determine the clinical significance of SULT1A2 in BC. Gene set enrichment analysis (GSEA) was performed to determine the potential biological processes and internal molecular mechanisms. The results demonstrated that SULT1A2 was highly expressed in BC tissues compared with ANBTs. Furthermore, high SULT1A2 expression was significantly associated with the staging of BC. Analyses of TCGA datasets and BC tissue microarray indicated that high SULT1A2 expression was significantly associated with a favorable overall survival in patients with BC. In addition, GSEA revealed pathways, diseases and biological processes associated with SULT1A2. Taken together, the results of the present study suggest that SULT1A2 acts as an oncogene in BC, and thus may serve as a biomarker for tumor staging and prognosis in patients with BC.
Identifiants
pubmed: 34055078
doi: 10.3892/etm.2021.10211
pii: ETM-0-0-10211
pmc: PMC8145616
doi:
Types de publication
Journal Article
Langues
eng
Pagination
779Informations de copyright
Copyright: © Chao et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Oncol Lett. 2018 Oct;16(4):4628-4634
pubmed: 30197677
Transl Androl Urol. 2017 Oct;6(5):785-790
pubmed: 29184774
N Engl J Med. 1971 Jan 21;284(3):129-34
pubmed: 5538681
Cancer. 1972 May;29(5):1250-60
pubmed: 5021618
Mol Pharmacol. 2005 Feb;67(2):394-9
pubmed: 15528404
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Rev Urol. 2019;21(1):23-28
pubmed: 31239827
J BUON. 2019 Jan-Feb;24(1):329-337
pubmed: 30941989
Asian Pac J Cancer Prev. 2013;14(8):4553-7
pubmed: 24083701
Cancers (Basel). 2011 Sep 28;3(4):3740-61
pubmed: 24213109
Fed Proc. 1987 May 15;46(7):2434-45
pubmed: 3552738
World J Urol. 2019 May;37(5):837-848
pubmed: 30171455
Breast Cancer Res Treat. 2010 Jul;122(2):337-46
pubmed: 19813088
Carcinogenesis. 2014 Aug;35(8):1814-22
pubmed: 24743514
Mol Carcinog. 2012 Dec;51(12):984-92
pubmed: 22006426
Cancer Causes Control. 2001 May;12(4):317-24
pubmed: 11456227
Carcinogenesis. 2008 Oct;29(10):1955-62
pubmed: 18632753
Br J Cancer. 2015 Jul 28;113(3):469-75
pubmed: 26125446
Future Oncol. 2009 Sep;5(7):1083-98
pubmed: 19792975
J Infect Dev Ctries. 2013 Aug 15;7(8):586-92
pubmed: 23949293
Cancer Res. 2005 Nov 15;65(22):10524-35
pubmed: 16288045
Br J Cancer. 2012 Jan 3;106(1):222-6
pubmed: 22116302
Mol Cells. 2018 Mar 31;41(3):188-197
pubmed: 29463068
World J Gastroenterol. 2010 Nov 7;16(41):5195-202
pubmed: 21049553
Cancer Res. 2010 Jan 15;70(2):832-41
pubmed: 20068172
Mod Pathol. 2012 Nov;25(11):1526-33
pubmed: 22684221
Pharmacol Ther. 2015 Jan;145:1-18
pubmed: 24929024
BMC Mol Biol. 2010 Aug 11;11:57
pubmed: 20701777
J Cancer. 2018 Apr 19;9(10):1754-1764
pubmed: 29805701
Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):559-66
pubmed: 16537716
Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):635-46
pubmed: 22512672
Cancer Res. 2005 Apr 1;65(7):2644-52
pubmed: 15805261
Front Oncol. 2020 Mar 27;10:394
pubmed: 32292720
Eur Urol. 2007 Aug;52(2):464-8
pubmed: 17116360
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Int J Mol Med. 2003 Jan;11(1):85-9
pubmed: 12469224
Anticancer Res. 2015 May;35(5):2513-9
pubmed: 25964524